Ind-Ra expects FY22 IPM to have witnessed 15% YoY sales growth, higher than the 8%-10% observed over the past five years, aided by the base effect
With this move, government hospitals across India can now access the geko device to prevent life-threatening blood clots, and address complications related to swelling following orthopaedic surgery and the healing of chronic wounds (leg ulcers)
The company’s differentiated value proposition comes during a time of unprecedented disruption in the life science supply chain
Recommendation based on Phase III PROVENT trial showing a significant reduction in the risk of developing symptomatic COVID-19, with protection lasting at least six months
Price was the key driver for the period
Meteoric Biopharmaceuticals have made rapid strides in the development of enzymes, probiotics and veterinary health products. It is seeking opportunities to scale up its growth backed by cutting edge R&D. Gaurav Kaushik, MD & CEO, Meteoric Biopharmaceuticals spoke to Thomas C Thottathil on the way forward
First of three Amneal biosimilars expected for U.S. approval and launch in 2022
Zerion´s innovative Dispersome technology builds on a new concept of increasing drug solubility by using natural protein-based excipients to formulate APIs into amorphous solid dispersions (ASDs) by spray drying
New subsidiaries to be established in Malaysia, Taiwan, Singapore, and Hong Kong
BDR Pharmaceuticals is a home-grown company with operations in India and overseas. It’s known for its formulations portfolio and has a presence in specialty medicines. The company has ambitious plans as it has ramped up capacity and looking to foray into regulated markets. Raheel Shah, Director, BDR Group of Companies shares his insights in an interview with Thomas C Thottathil, Editor, Indian Pharma Post
Subscribe To Our Newsletter & Stay Updated
